Annual return of 118.79% - See How Click here now!
MarketTelegraph.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420.
-------------------------------------------
Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) closed at $4.74 Tuesday, trading 127,000 shares.
Company News- September 30, 2008: Cytokinetics to Present at JMP Securities Healthcare Focus Conference
Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced yesterday that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008, at 9:30 a.m. Eastern Time at the Le Parker Meridian Hotel, New York, New York.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is conducting a Phase I clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-nave patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting a Phase I trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
-------------------------------------------
Fulton Financial Corporation (NASDAQ: FULT | Quote | Chart | News | PowerRating) closed at $10.91 Tuesday, trading 1,077,500 shares.
Company News- September 30, 2008: Fulton Financial Corporation Announces Dates for Third Quarter Earnings Release and Conference Call/Webcast
Fulton Financial Corporation (NASDAQ: FULT | Quote | Chart | News | PowerRating) yesterday announced that it will distribute its third quarter earnings news release and accompanying charts on Tuesday, October 21 at approximately 4:30 p.m. Eastern Time.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About Fulton Financial Corporation
Fulton Financial Corporation is a financial holding company that operates 270 banking offices in Pennsylvania, Maryland, Delaware, New Jersey and Virginia through the following affiliates: Fulton Bank, Lancaster, PA; Swineford National Bank, Middleburg, PA; Lafayette Ambassador Bank, Easton, PA; FNB Bank, N.A., Danville, PA; Hagerstown Trust, Hagerstown, MD; Delaware National Bank, Georgetown, DE; The Bank, Woodbury, NJ; Peoples Bank of Elkton, Elkton, MD; Skylands Community Bank, Hackettstown, NJ; and The Columbia Bank, Columbia, MD.
The Corporation's additional financial services providers include Fulton Financial Advisors, N.A., Lancaster, PA; Fulton Insurance Services Group, Inc., Lancaster, PA; and Dearden, Maguire, Weaver and Barrett, LLC, West Conshohocken, PA. Residential mortgage lending is offered by all banks through Fulton Mortgage Company.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. MarketTelegraph.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.businessnetwire.us, www.financialbusinessnews.us, www.fastmoneytalk.com, www.associatesfortune.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage
CONTACT: Markettelegraph.com Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.markettelegraph.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
